The New England journal of medicine, 2021-09, Vol.385 (13), p.1196-1206
- Nathan, Paul
- Hassel, Jessica C
- Rutkowski, Piotr
- Baurain, Jean-Francois
- Butler, Marcus O
- Schlaak, Max
- Sullivan, Ryan J
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M
- Joshua, Anthony M
- Sacco, Joseph J
- Shoushtari, Alexander N
- Orloff, Marlana
- Piulats, Josep M
- Milhem, Mohammed
- Salama, April K.S
- Curti, Brendan
- Demidov, Lev
- Gastaud, Lauris
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D
- Hamid, Omid
- Abdullah, Shaad E
- Holland, Chris
- Goodall, Howard
- Piperno-Neumann, Sophie
2021
Details
- Autor(en) / Beteiligte
- Nathan, Paul
- Hassel, Jessica C
- Rutkowski, Piotr
- Baurain, Jean-Francois
- Butler, Marcus O
- Schlaak, Max
- Sullivan, Ryan J
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M
- Joshua, Anthony M
- Sacco, Joseph J
- Shoushtari, Alexander N
- Orloff, Marlana
- Piulats, Josep M
- Milhem, Mohammed
- Salama, April K.S
- Curti, Brendan
- Demidov, Lev
- Gastaud, Lauris
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D
- Hamid, Omid
- Abdullah, Shaad E
- Holland, Chris
- Goodall, Howard
- Piperno-Neumann, Sophie
- Titel
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- Ist Teil von
- The New England journal of medicine, 2021-09, Vol.385 (13), p.1196-1206
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Metastatic uveal melanoma is an aggressive disease without an established standard treatment. In a randomized trial that evaluated tebentafusp, a soluble T-cell receptor bispecific protein, overall survival at 1 year was 73% among patients who received tebentafusp, as compared with 59% among those who received the investigator’s choice of therapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2103485Titel-ID: cdi_proquest_miscellaneous_2575828513
- Format
- –
- Schlagworte
- Adult, Adverse events, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - therapeutic use, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Cancer, CD3 antigen, Cell activation, Cytokine Release Syndrome - chemically induced, Cytokines, Dacarbazine, Dacarbazine - therapeutic use, Dermatology, Drug therapy, Exanthema - chemically induced, Eye cancer, Female, Fever, Hematology, Histocompatibility antigen HLA, Humans, Immunotherapy, Ipilimumab - therapeutic use, L-Lactate dehydrogenase, Lactic acid, Lymphocytes T, Male, Medical prognosis, Melanocytes, Melanoma, Melanoma - drug therapy, Melanoma - mortality, Melanoma - secondary, Metastases, Metastasis, Middle Aged, Oncology, Oncology, Experimental, Patients, Pembrolizumab, Peptides, Population, Pruritus, Recombinant Fusion Proteins - adverse effects, Recombinant Fusion Proteins - therapeutic use, Skin Cancer, Survival Analysis, T-cell receptor, Treatments in Oncology, Uveal Neoplasms - drug therapy, Uveal Neoplasms - mortality, Uveal Neoplasms - pathology